Moreover, in a study by Zhou et al., 2009, Luteolin was shown to inhibit the invasion of PC3 prostate cancer cells by inducing E-cadherin expression, where the induction of the E-cadherin expression by Luteolin was found to occur through the MDM2 protein, as the invasion of PC3 cells by overexpressing MDM2 or knockdown of E-cadherin could be restored after Luteolin treatment [76]. The gene discussed is MDM2; the disease is prostate carcinoma.